Evidence map›Paper›PMID 36769161›Full record

ArticleInternational journal of molecular sciences2023

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model.

Tianqi Xu, Alexey Schulga, Elena Konovalova, Sara S Rinne, Hongchao Zhang, Olga Vorontsova, Anna Orlova, Sergey M Deyev, Vladimir Tolmachev, Anzhelika Vorobyeva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Special Issue "Bacterial Toxins and Cancer".International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tianqi XuDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0002-1826-4093
Alexey SchulgaResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, National Research Tomsk Polytechnic University, Tomsk 634050, Russia.ORCID 0000-0003-3425-0828
Elena KonovalovaMolecular Immunology Laboratory, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.
Sara S RinneDepartment of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden.ORCID 0000-0003-2141-3982
Hongchao ZhangDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.
Olga VorontsovaDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.
Anna OrlovaResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, National Research Tomsk Polytechnic University, Tomsk 634050, Russia.ORCID 0000-0001-6120-2683
Sergey M DeyevResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, National Research Tomsk Polytechnic University, Tomsk 634050, Russia.ORCID 0000-0002-3952-0631
Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0002-6122-1734
Anzhelika VorobyevaDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0002-4778-3909

Funding

Linnéstiftelsen för medicinsk forskning 2020-01-24Swedish Cancer Society 20 0181 PSwedish Cancer Society 20 0893 Pjthe Swedish Research Council 2022-01519
6 · The paper itself

Abstract

Pancreatic cancer (PC) is one of the most aggressive malignancies. A combination of targeted therapies could increase the therapeutic efficacy in tumors with heterogeneous target expression. Overexpression of the human epidermal growth factor receptor type 3 (HER3) and the epithelial cell adhesion molecule (EpCAM) in up to 40% and 30% of PCs, respectively, is associated with poor prognosis and highlights the relevance of these targets. Designed ankyrin repeat protein (DARPin) Ec1 fused with the low immunogenic bacterial toxin LoPE provides specific and potent cytotoxicity against EpCAM-expressing cancer cells. Here, we investigated whether the co-targeting of HER3 using the monoclonal antibody seribantumab (MM-121) and of EpCAM using Ec1-LoPE would improve the therapeutic efficacy in comparison to the individual agents. Radiolabeled

Indexed as

Designed Ankyrin Repeat ProteinsPancreatic NeoplasmsAnimalsAntibodies, Monoclonal, HumanizedCell Line, TumorDisease Models, AnimalEpithelial Cell Adhesion MoleculeFeasibility StudiesHeterograftsHumansMiceXenograft Model Antitumor AssaysAntibodies, Monoclonal, HumanizedDesigned Ankyrin Repeat ProteinsEPCAM protein, humanEpithelial Cell Adhesion Moleculeseribantumabcombination treatmentDARPinEpCAMHER3MM-121pancreatic cancerpseudomonas exotoxin Atargeted therapy

Identifiers

PMID36769161
PMCPMC9917732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.